Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT by...License Agreement • March 10th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of December 22, 2022 (the “Effective Date”), by and among Akebia Therapeutics, Inc., a Delaware corporation with its principal place of business at 245 First Street, Cambridge, MA 02142 and its Subsidiary, Keryx Biopharmaceuticals, Inc. (“Keryx,” and collectively, “Akebia”), on the one hand, and Averoa SAS, an French corporation, having a place of business at 11 avenue Paul Verlaine, 38100 Grenoble, France, represented by Luc-André Granier in his capacity as CEO, duly empowered for the purposes hereof (“Licensee”) on the other hand. Akebia and Licensee may, from time to time, be individually referred to as a “Party” and collectively referred to as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO.1 TO...Collaboration Agreement • March 10th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO.1 TO COLLABORATION AGREEMENT (this “Amendment No. 1” ) is effective as of December 2, 2022 (the “Effective Date” ) and made by and between:
CONFIDENTIAL Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote...Termination Agreement • March 10th, 2023 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This termination and settlement agreement (the “Termination Agreement”) shall be effective as of December 22, 2022 (the “Termination Effective Date”) between Keryx Biopharmaceuticals, Inc. (“Keryx”), a wholly-owned subsidiary of Akebia Therapeutics, Inc. (“Akebia”), with a place of business at 245 First Street, Cambridge, Massachusetts, 02142, USA, and BIOVECTRA Inc., with a place of business at 11 Aviation Avenue, Charlottetown, Prince Edward Island, C1E0A1, Canada (“BIOVECTRA”) to terminate any and all existing agreements entered into by the parties in connection with the manufacture and supply, by BIOVECTRA to Akebia, of Akebia’s proprietary active pharmaceutical ingredient, ferric citrate drug substance (the “Product”). Akebia (on behalf of itself and Keryx) and BIOVECTRA are each referred to individually as a “Party,” and collectively as the “Parties” to this Termination Agreement.
